logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Chronic Kidney Diseases

    Medications for Chronic Kidney Diseases

    FiltersReset Filters
    14 results

    • farxiga

      (DAPAGLIFLOZIN)
      AstraZeneca Pharmaceuticals LP
      Usage: FARXIGA (dapagliflozin) is indicated for reducing risks associated with chronic kidney disease, heart failure, and for improving glycemic control in adults and pediatric patients (10 years and older) with type 2 diabetes mellitus, alongside diet and exercise. It is not recommended for type 1 diabetes or specific kidney conditions.

    • ferrlecit

      (sodium ferric gluconate complex)
      sanofi-aventis U.S. LLC
      Usage: Ferrlecit is indicated for treating iron deficiency anemia in adults and pediatric patients aged 6 and older with chronic kidney disease undergoing hemodialysis and receiving supplemental epoetin therapy.

    • furoscix

      (furosemide injection 80 mg/ 10 mL)
      scPharmaceuticals Inc.
      Usage: FUROSCIX is indicated for treating edema in adults with chronic heart failure or chronic kidney disease (CKD), including those with nephrotic syndrome.

    • injectafer

      (Ferric Carboxymaltose Injection)
      American Regent, Inc.
      Usage: Injectafer is indicated for treating iron deficiency anemia in patients aged 1 year and older with oral iron intolerance or unsatisfactory response, and in non-dialysis dependent chronic kidney disease. It also treats iron deficiency in adults with heart failure (NYHA class II/III) to improve exercise capacity.

    • kerendia

      (finerenone)
      Bayer Healthcare Pharmaceuticals Inc.
      Usage: Kerendia is indicated for reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.

    • ozempic

      (semaglutide)
      Novo Nordisk
      Usage: OZEMPIC is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. It also reduces the risk of major adverse cardiovascular events and helps in preventing kidney disease progression in patients with type 2 diabetes and chronic kidney disease.

    • renvela

      (SEVELAMER CARBONATE)
      Genzyme Corporation
      Usage: Renvela (sevelamer carbonate) is indicated for controlling serum phosphorus levels in adults and children aged 6 and older with chronic kidney disease (CKD) who are on dialysis.

    • sevelamer carbonate

      (SEVELAMER CARBONATE)
      Shandong Xinhua Pharmaceutical Co., Ltd.
      Usage: Sevelamer carbonate tablets are indicated for controlling serum phosphorus levels in adults and children aged 6 years and older with chronic kidney disease (CKD) who are undergoing dialysis.

    • sevelamer carbonate

      (Sevelamer Carbonate)
      Winthrop U.S, a business of sanofi-aventis U.S. LLC
      Usage: Sevelamer carbonate is indicated for controlling serum phosphorus levels in adults and children aged 6 and older with chronic kidney disease (CKD) undergoing dialysis.

    • sevelamer hydrochloride

      (Sevelamer Hydrochloride)
      Winthrop U.S, a business of sanofi-aventis U.S. LLC
      Usage: Sevelamer hydrochloride is indicated for controlling serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis. Its safety and efficacy in CKD patients not on dialysis have not been evaluated.